Eye drops could keep Kids' vision from getting worse

NCT ID NCT07626892

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested three low doses of atropine eye drops (0.01%, 0.03%, and 0.05%) in 95 children aged 6–18 with nearsightedness. The goal was to see which dose best slowed the worsening of myopia with the fewest side effects. Over 18 months, the 0.05% dose worked best at controlling vision changes, while all doses were generally well-tolerated.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
atropine eye drops (low concentrations 0.01%, 0.03%, 0.05%)
What this could lead to
If confirmed, this could give doctors a safe, effective way to slow worsening nearsightedness in children, reducing their risk of serious eye problems later in life.
What could go wrong
This was a small, single-country study. The results may not apply to all children, and long-term safety beyond 18 months is not yet known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATROPINE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Khyber Teaching Hospital

    Peshawar, KPK, 25000, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.